Literature DB >> 2370687

Human T-cell leukemia virus type I trans activator induces class I major histocompatibility complex antigen expression in glial cells.

M Sawada1, A Suzumura, M Yoshida, T Marunouchi.   

Abstract

Transfection of the tax gene encoding the trans activator of human T-cell leukemia virus type I into glial line cells induced class I major histocompatibility complex (MHC) antigens on these cells. This occurred through the interaction of tax protein with the gene encoding class I MHC antigens but not through any soluble factors, such as interferons, or factors from glial cells. Since neural cells do not usually express MHC antigens, this novel mechanism may be an intermediate event between viral infection and subsequent immune-mediated pathology in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2370687      PMCID: PMC249700     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

Review 1.  Binding of viral attachment protein to host-cell receptor: the Achilles heel of infectious viruses.

Authors:  T L Lentz
Journal:  Trends Pharmacol Sci       Date:  1988-07       Impact factor: 14.819

2.  Expression of H-2 antigen on oligodendrocytes is induced by soluble factors from concanavalin A activated T cells.

Authors:  A Suzumura; D H Silberberg
Journal:  Brain Res       Date:  1985-06-10       Impact factor: 3.252

3.  Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease.

Authors:  M Yoshida; M Seiki; K Yamaguchi; K Takatsuki
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

4.  Inducible expression of H-2 and Ia antigens on brain cells.

Authors:  G H Wong; P F Bartlett; I Clark-Lewis; F Battye; J W Schrader
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

5.  Antigens encoded by the 3'-terminal region of human T-cell leukemia virus: evidence for a functional gene.

Authors:  T H Lee; J E Coligan; J G Sodroski; W A Haseltine; S Z Salahuddin; F Wong-Staal; R C Gallo; M Essex
Journal:  Science       Date:  1984-10-05       Impact factor: 47.728

6.  Homology of human T-cell leukaemia virus envelope gene with class I HLA gene.

Authors:  M F Clarke; E P Gelmann; M S Reitz
Journal:  Nature       Date:  1983 Sep 1-7       Impact factor: 49.962

7.  Cell lines producing human T-cell lymphoma virus show altered HLA expression.

Authors:  D L Mann; M Popovic; P Sarin; C Murray; M S Reitz; D M Strong; B F Haynes; R C Gallo; W A Blattner
Journal:  Nature       Date:  1983 Sep 1-7       Impact factor: 49.962

8.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

9.  Multiple sclerosis and human T-cell lymphotropic retroviruses.

Authors:  H Koprowski; E C DeFreitas; M E Harper; M Sandberg-Wollheim; W A Sheremata; M Robert-Guroff; C W Saxinger; M B Feinberg; F Wong-Staal; R C Gallo
Journal:  Nature       Date:  1985 Nov 14-20       Impact factor: 49.962

10.  Complete nucleotide sequence of a functional class I HLA gene, HLA-A3: implications for the evolution of HLA genes.

Authors:  T Strachan; R Sodoyer; M Damotte; B R Jordan
Journal:  EMBO J       Date:  1984-04       Impact factor: 11.598

View more
  23 in total

1.  Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein.

Authors:  J M Johnson; C Nicot; J Fullen; V Ciminale; L Casareto; J C Mulloy; S Jacobson; G Franchini
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  trans activation of the tumor necrosis factor alpha promoter by the human T-cell leukemia virus type I Tax1 protein.

Authors:  H Albrecht; A N Shakhov; C V Jongeneel
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

3.  Temporal regulation of viral and cellular gene expression during human T-lymphotropic virus type I-mediated lymphocyte immortalization.

Authors:  J T Kimata; L Ratner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  Transcriptional regulation of MHC class I gene expression in rat oligodendrocytes.

Authors:  G Mavria; K T Hall; R A Jones; G E Blair
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

Review 5.  Mechanisms of T-cell activation by human T-cell lymphotropic virus type I.

Authors:  P Höllsberg
Journal:  Microbiol Mol Biol Rev       Date:  1999-06       Impact factor: 11.056

6.  Tax induces nuclear translocation of NF-kappa B through dissociation of cytoplasmic complexes containing p105 or p100 but does not induce degradation of I kappa B alpha/MAD3.

Authors:  E Muñoz; G Courtois; P Veschambre; P Jalinot; A Israël
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  The mitogenic activity of human T-cell leukemia virus type I is T-cell associated and requires the CD2/LFA-3 activation pathway.

Authors:  J T Kimata; T J Palker; L Ratner
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

8.  Dendritic cells infected in vitro with human T cell leukaemia/lymphoma virus type-1 (HTLV-1); enhanced lymphocytic proliferation and tropical spastic paraparesis.

Authors:  A Ali; S Patterson; K Cruickshank; P Rudge; A G Dalgleish; S C Knight
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

9.  Neuroaxonal dystrophy in HTLV-1-associated myelopathy/tropical spastic paraparesis: neuropathologic and neuroimmunologic correlations.

Authors:  E Wu; D W Dickson; S Jacobson; C S Raine
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

10.  The presence of HTLV-I proviral DNA in the central nervous system of patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.

Authors:  J Kira
Journal:  Mol Neurobiol       Date:  1994 Apr-Jun       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.